Climate Equity
Economic Empowerment
Healthy Ageing

Healthy ageing

Enabling healthier lives for longer

What is healthy ageing?

We are particularly interested in companies addressing women’s health; mental health; metabolic syndromeconditions including cardiovascular disease, obesity, fatty liver disease (NASH) and diabetes.

Why healthy ageing?

1

We want to deepen medical research into the impact of sex and race on health and improve the participation of underserved groups in clinical trials.

2

We want to improve health outcomes for those from underserved groups, particularly in metabolic health, fertility and longevity research.

3

We want to ensure the social determinants of health (finances, work, housing, environment etc) are contributing to longer, more active lives.

Examples of healthy ageing companies we’ve invested in recently:

We led a
seed round of
c.£1m
with
Entrepreneur First, Ace Cap and angels

We co-led
a seed round of
£5m
with
Hoxton Ventures, MMC and Verve


We led a
pre-seed round of
£500k
with angels


We led a
pre-seed round of
£1.75m
with Entrepreneur First, Samos Investments and Saras Capital

Which areas do we invest in?

About 70% of the healthcare investments in the fund go to health technology and AI companies. Around 30% of the fund goes to tech-bio companies (primarily software).

We are particularly interested in companies addressing women’s health, mental health, and metabolic syndrome conditions.

Innovations we like:

  • Workflow tools improving automation and making the delivery of healthcare more accessible and affordable.
  • Software enabling the stratification of patient groups and intelligent, personalised delivery of care to these groups.
  • Fintech software providing business models and payment solutions to improve outcomes for patients and service providers.
  • Software auditing and explaining why clinical decisions are being made and what the influence of AI on the treatment pathway.
  • Adoption of tools used in non-healthcare settings for clinical trials & drug discovery thus increasing efficiency across patient journey and drug development.

What compels us to back a company in this area?

The context

Our health and biotech ecosystem in the UK is a Petri dish for innovation. There is data provided by the NHS and healthcare organisations; world-class universities in life sciences; a strong traditional pharmaceuticals industry; and scaling health-tech and tech-bio companies full of talent.

The company

  • A cutting-edge scientific breakthrough or a meaningful (10x) improvement to current workflows.
  • The opportunity for massive value creation (£100m revenue with five years) and uncapped upside.
  • The ability to positively impact an underserved group.

The founders

  • Founders driven by generating meaningful positive social impact on tens of millions of people, as well as huge commercial success in parallel.
  • Founders with an evidence-first approach to their solutions – they have already run small pilot studies or are planning on feedback loops to track and report efficacy of their interventions.
  • Founders with a strong commercial track record of being able to sell into clinical care settings or hospitals, and have experience selling internationally into both public and private systems.
  • Founders with a strong technology grounding or ability to get a product built and tested with customers and iterate fast.
  • Companies with the ability to get a product to market within six months of our investment, or a product already in the market.

Main reasons we pass

  • Founders raising a large round without validation from early customers.
  • Lack of unique technology or defensibility.
  • Concern about the founder’s commercial ability.
  • Concerns about the size of the opportunity and company scalability.

Building a company tackling an important problem in healthy ageing?

Come and talk to us

Sign up for our newsletter

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Team

Portfolio

Sourcing Network

Talent Network

Ada Ventures London, United House, 9 Pembridge Road, Notting Hill, London, W11 3JY. Ada Ventures Bristol, 17 Berkeley Square, Bristol, BS8 1HB. Ada Partners LLP is a limited liability partnership registered in England and Wales under number OC423404, with its registered office at United House, 9 Pembridge Road, Notting Hill, London, W11 3JY. Ada Partners LLP is authorised and regulated by the Financial Conduct Authority with firm reference number 814738.

Privacy NoticeCode of Conduct PolicyTerms of Use